Cogent Biosciences, Inc.
COGT$773M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWALTHAM205 employees
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 4, 2026
6wMarket Overview
Stock performance and key metrics
COGT News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
CGT9486 plus sunitinib
Advanced Gastrointestinal Stromal Tumors
CGT9486
Gastrointestinal Stromal Tumors
bezuclastinib
Advanced Systemic Mastocytosis (AdvSM)
Bezuclastinib Tablets (Formulation A)
SSM
CGT4859
Intrahepatic Cholangiocarcinoma (Icc)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CGT9486 plus sunitinib | Phase 3 | Advanced Gastrointestinal Stromal Tumors | - | - |
CGT9486 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
bezuclastinib | Phase 2 | Advanced Systemic Mastocytosis (AdvSM) | - | - |
Bezuclastinib Tablets (Formulation A) | Phase 2 | SSM | - | - |
CGT4859 | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply